Medical Imaging for Radiotherapy

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".

Deadline for manuscript submissions: closed (10 October 2022) | Viewed by 2006

Special Issue Editors


E-Mail Website
Guest Editor
Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, 16100 Genova, Italy
Interests: radiotherapy; imaging; SABR; lung cancer; onco-hematology; melanoma

E-Mail Website
Guest Editor
Institute of Radiation Physics, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland
Interests: machine learning; convolutional neural networks; automation in treatment planning; target motion management; deformable image registration (DIR)

E-Mail Website
Guest Editor
Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Verona, Italy
Interests: SABR; oligometastatic; lung cancer; radiotherapy

Special Issue Information

Dear Colleagues,

Radiotherapy was born from radiological imaging more than one hundred years ago and evolved over the years to stop being a rib of radiodiagnostic but starring in cancer cure. However, most of the clinical workflow in radiation oncology is still tied to imaging. The target definition, usually delineated on a conventional CT scan, can often be integrated with multimodality imaging to identify cancer boundaries and a tumor’s proliferative heterogeneity or with dedicated technology to reduce uncertainties for organ motion. The second important step in the workflow is the physics planning calculation, a core based on imaging voxel information. Another step is the radiation dose delivery, guided by the imaging onboard the linear accelerators (IGRT) to assess the precision to hit the target and avoid healthy tissues. Then, at last, imaging is also used to evaluate the response at the end of the radiation treatment. Today, all these steps are undergoing frequent updates due to the highly flourishing research on medical imaging, physics, and radiotherapy. 

This Special Issue aims to offer the opportunity to all the researchers and clinicians involved in radiation oncology to publish scientific revisions of this changing world or present their early results from original and promising research on:

  • Multiparametric or metabolic imaging (MRI, PET) for target definition or predicting the radiation response;
  • Radiomics and radiotherapy;
  • Treatment planning on synthetic CT images;
  • Implementation and validation of automatic solutions for treatment planning;
  • Deformable image registration (DIR): potential applications in radiotherapy;
  • Target delineation with organ motion management via 4D CT or cine MRI;
  • Image-Guided Radiotherapy (IGRT) by MRI or any advanced technique for organ motion control;
  • Imaging and strategy for “Adaptive” radiotherapy, with or without re-planning;
  • The best imaging to assess response to radiation.

Dr. Stefano Vagge
Dr. Michele Zeverino
Dr. Niccolò Giaj-Levra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • IGRT
  • adaptive radiotherapy
  • radiomics
  • MRI
  • molecular imaging
  • advanced radiotherapy
  • 4DCT
  • organ motion
  • image reconstruction
  • image registration
  • automatic planning

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

10 pages, 1367 KiB  
Article
Thymic Hyperplasia and COVID-19 Pulmonary Sequelae: A Bicentric CT-Based Follow-Up Study
by Michaela Cellina, Maurizio Cè, Andrea Cozzi, Simone Schiaffino, Deborah Fazzini, Enzo Grossi, Giancarlo Oliva, Sergio Papa and Marco Alì
Appl. Sci. 2024, 14(9), 3930; https://doi.org/10.3390/app14093930 - 5 May 2024
Viewed by 503
Abstract
This study aimed to investigate the role of the thymus in influencing long-term outcomes of COVID-19 by comparing the thymic appearance in patients with and without COVID-19 pulmonary sequelae at chest computed tomography (CT). A total of 102 adult patients previously hospitalized for [...] Read more.
This study aimed to investigate the role of the thymus in influencing long-term outcomes of COVID-19 by comparing the thymic appearance in patients with and without COVID-19 pulmonary sequelae at chest computed tomography (CT). A total of 102 adult patients previously hospitalized for COVID-19 underwent a follow-up chest CT three months after discharge. Pulmonary sequelae and thymic appearance were independently assessed by two experienced radiologists. The thymus was detectable in 55/102 patients (54%), with only 7/55 (13%) having any kind of pulmonary sequelae, compared to 33 out of 47 (70%, p < 0.001) in patients without thymic visibility, as confirmed in age-stratified analysis and at logistic regression analysis, where thymic involution had a 9.3 odds ratio (95% CI 3.0–28.2, p < 0.001) for the development of pulmonary sequelae. These results support the hypothesis that thymic reactivation plays a protective role against adverse long-term outcomes of COVID-19. Full article
(This article belongs to the Special Issue Medical Imaging for Radiotherapy)
Show Figures

Figure 1

Other

Jump to: Research

7 pages, 1509 KiB  
Brief Report
A Brief Report on the Role of SPECT/TC in the Optimization of Radiotherapy Treatment with Radical Intent for Unresectable Stage III NSCLC
by Jessica Imbrescia, Giulia Volpi, Silvia Lucchini, Cristian Toraci, Giorgio Facheris, Salvatore La Mattina, Navdeep Singh, Filippo Vaccher, Andrea Guerini, Michela Buglione di Monale e Bastia, Alessio Bruni and Paolo Borghetti
Appl. Sci. 2022, 12(18), 9351; https://doi.org/10.3390/app12189351 - 18 Sep 2022
Viewed by 1058
Abstract
Background: The standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is represented by concomitant chemo-radiotherapy followed by consolidation with durvalumab that ensures a 5-year survival of 46%. However, the risk of radiotherapy-induced pneumonia (RIP) is almost 10–15%. Complete cardiological examination is [...] Read more.
Background: The standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is represented by concomitant chemo-radiotherapy followed by consolidation with durvalumab that ensures a 5-year survival of 46%. However, the risk of radiotherapy-induced pneumonia (RIP) is almost 10–15%. Complete cardiological examination is also usually performed during the cardiopulmonary pre-treatment evaluation and pulmonary function testing is one of the most used tool to predict the risk of RIP development. Aim: The aim of this study is to investigate the impact of Tc-99 macroaggregated albumin (MAA) lung perfusion scan with single photon emission-computed tomography/computed tomography (SPECT/CT) in the preliminary assessment of lung functions and its potential role for the optimization of the radiotherapy treatment planning. Methods: Descriptive and statistical analysis were performed on eight patients affected by unresectable stage III LA-NSCLC treated with chemo-radiotherapy. Before starting radiotherapy, patients underwent lung perfusion SPECT/CT. The SPECT/CT images were firstly co-registered with the simulation CT scan ones, then a specific region of interest (ROI) of lung volumes was created to represent the areas with a perfusion of at least 20% 40%, 60% and 80% of maximum perfusion, respectively. Finally, optimization of the standard treatment plan was performed with the aim of preserving the better perfused lung volumes. The dosimetric correlations of both plans were made comparing pulmonary V20 and V5, mean pulmonary, esophagus and heart dose. Results: From the DVH comparative analysis of the two treatment plans (standard one versus SPECT optimized one) obtained for each patient, the data confirmed an equal coverage of the target volume while respecting all lungs, heart and esophagus dose constraints. At the same time, SPECT-optimized plans allowed to reduce the average dose to the better perfused lung volumes. Conclusions: Lung perfusion scintigraphy could be considered a preliminary assessment tool to explore lung functions and stratify the risk of RIP development. SPECT/TC may also be proposed as a dose painting tool to optimize radiotherapy treatment plans. Only prospective analysis will be enable us to confirm the real reduction of RIP risk in lung areas with an optimal perfusion. Full article
(This article belongs to the Special Issue Medical Imaging for Radiotherapy)
Show Figures

Figure 1

Back to TopTop